Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NECITUMUMAB Cause Infection? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Infection have been filed in association with NECITUMUMAB (Portrazza). This represents 1.6% of all adverse event reports for NECITUMUMAB.

6
Reports of Infection with NECITUMUMAB
1.6%
of all NECITUMUMAB reports
2
Deaths
1
Hospitalizations

How Dangerous Is Infection From NECITUMUMAB?

Of the 6 reports, 2 (33.3%) resulted in death, 1 (16.7%) required hospitalization.

Is Infection Listed in the Official Label?

Yes, Infection is listed as a known adverse reaction in the official FDA drug label for NECITUMUMAB.

What Other Side Effects Does NECITUMUMAB Cause?

Platelet count decreased (68) Malignant neoplasm progression (54) Rash (48) Hypomagnesaemia (46) Neutrophil count decreased (45) Dermatitis acneiform (44) Febrile neutropenia (30) Decreased appetite (29) Neutropenia (26) Nausea (21)

What Other Drugs Cause Infection?

ADALIMUMAB (11,552) METHOTREXATE (10,406) ETANERCEPT (10,379) RITUXIMAB (9,575) ABATACEPT (7,821) TOCILIZUMAB (7,349) PREDNISONE (6,334) TOFACITINIB (6,332) INFLIXIMAB (6,122) CERTOLIZUMAB PEGOL (5,954)

Which NECITUMUMAB Alternatives Have Lower Infection Risk?

NECITUMUMAB vs NEDAPLATIN NECITUMUMAB vs NEFAZODONE NECITUMUMAB vs NEFOPAM NECITUMUMAB vs NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE\NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIG NECITUMUMAB vs NELARABINE

Related Pages

NECITUMUMAB Full Profile All Infection Reports All Drugs Causing Infection NECITUMUMAB Demographics